Warfarin is an anticoagulant drug with narrow therapeutic index and high interindividual variability in dose requirement. S-warfarin is metabolized mainly by polymorphic cytochrome P450 (CYP) 2C9. We systematically quantified the influence of CYP2C9 genotype, demographic factors and concomitant drug treatment on warfarin metabolism and maintenance dose. The mean warfarin doses were lower in carriers of one (2.71 mg/day, 59 patients) and two polymorphic alleles (1.64 mg/day, 11 patients) than in carriers of two wild-type alleles (4.88 mg/day, 118 patients). Multiple regression analysis demonstrated that CYP2C9 genotype, age, concomitant treatment with warfarin metabolism inducers and lean body weight contributed significantly to interindividual variability in warfarin dose requirement (adjusted R 2 ¼ 0.37). The same factors, except for age, significantly influenced S-warfarin clearance (adjusted R 2 ¼ 0.42). These results can serve as a starting point for designing prospective studies in patients in the initiation phase of genotype-based warfarin therapy.
INTRODUCTION
Warfarin is an oral anticoagulant drug and the most common coumarin that is in clinical use. 1 Its narrow therapeutic index and high interindividual variability in the dose required to achieve the desired therapeutic effect complicate the treatment. Despite careful monitoring of prothrombin time (PT) expressed as International Normalized Ratio (INR), bleeding events are likely to occur and the risk of serious hemorrhage during warfarin therapy ranges from 1.3 to 4.2 per 100 patient years of exposure. 2 Warfarin is clinically available as racemate, which is a mixture of equal amounts of S-and R-warfarin. S-warfarin exhibits a three-to five-fold higher inhibitory effect on the target enzyme vitamin K 1 2,3 epoxide reductase. Both enantiomers are metabolized by cytochrome P450's (CYP), but differ considerably in the sites of hydroxylation and P450 enzymes involved. S-warfarin is metabolized almost exclusively by CYP2C9 to 7-hydroxywarfarin, whereas CYP1A2, CYP2C19 and CYP3A4 are responsible for the oxidative metabolism of the R-enantiomer. 3 Owing to the more extensive metabolism of the S-enantiomer than the R-enantiomer, its plasma concentrations are approximately two-fold lower than that of the R-enantiomer. 4 Genetic polymorphisms of the CYP2C9 gene, which give rise to proteins with altered catabolic activity, have been described. The two most common variant alleles in Caucasian populations are CYP2C9*2 with a point mutation in exon 3 causing Arg 144 Cys exchange and CYP2C9*3 with a point mutation in exon 7 causing Ile 359 Leu exchange. 5, 6 The frequencies of CYP2C9*2 and CYP2C9*3 alleles in our population were 0.122 and 0.063, respectively, and were similar to those in other Caucasian populations. 7, 8 It has been demonstrated that carriers of polymorphic alleles require significantly lower doses of warfarin than carriers of two wild-type alleles. Patients with polymorphic CYP2C9 alleles were reported to be more susceptible to bleeding complications. 9 Although the influence of CYP2C9 polymorphism on either warfarin dose requirement or susceptibility to bleeding complications has been extensively studied, 2, [10] [11] [12] [13] [14] [15] [16] only two studies so far have addressed the influence of genotype on both the dose requirement and warfarin metabolism. 17, 18 However, to confirm significant differences in anticoagulant response among different groups of patients, the sample size should have been bigger and the patients more homogeneous regarding their indication for warfarin treatment.
The influence of other factors such as physiological status, accompanying disease and concomitant drug treatment, which may contribute to variation in warfarin metabolism in addition to genetic polymorphism, has been less systematically studied. To address this issue, we designed a systematic study on a large and clinically homogeneous group of patients to determine the influence of CYP2C9 genotype, demographic factors (age, lean body weight (LBW), duration of warfarin therapy, plasma albumin concentration, vegetable and grapefruit intake) and concomitant drug treatment on warfarin metabolism and its maintenance dose.
RESULTS

Genotyping and Pharmacokinetic Analysis
In total, 188 patients on warfarin maintenance therapy were included in genotyping and pharmacokinetic analysis. The descriptive data of the patients are summarized in Table 1 .
The patients were analyzed for CYP2C9 polymorphism, and six different genotypes were detected. Out of 188 patients, 118 were homozygous for the wild-type allele and 59 patients carried one of the polymorphic alleles (n ¼ 32 for CYP2C9*2, n ¼ 27 for CYP2C9*3). In all, 11 patients had both alleles polymorphic (n ¼ 2 for CYP2C9*2/*2, n ¼ 6 for CYP2C9*2/*3, n ¼ 3 for CYP2C9*3/*3). The daily warfarin doses ranged from 0.54 to 14.36 mg with a mean (SD) of 4.01 (2.64) mg. The mean warfarin maintenance dose was highest among patients with CYP2C9*1/*1 genotype (4.96 mg/day) and differed significantly from mean warfarin doses required by patients with other genotypes (Po0.001), except for two patients with CYP2C9*2/*2 genotype (2.95 mg/day). The patients with CYP2C9*1/*2 genotype had a higher mean warfarin dose (2.98 mg/day) than those with CYP2C9*1/*3 (2.39 mg/day); however, the difference was not significant. The patients with CYP2C9*2/*3 genotype had a lower mean warfarin dose (1.53 mg/day) than the patients with one polymorphic allele, but the difference was significant only for CYP2C9*1/*2 genotype (P ¼ 0.007). The patients with CYP2C9*3/*3 genotype had the lowest mean warfarin dose (1.00 mg/day), which differed significantly from all the other genotypes (P ¼ 0.05) except CYP2C9*2/*3. The influence of CYP2C9 genotype on warfarin maintenance dose is presented in Figure 1 .
Owing to the small numbers of patients with genotypes CYP2C9*2/*2, CYP2C9*2/*3 and CYP2C9*3/*3, the patients were pooled into three genotype subgroups for further statistical analysis of pharmacokinetic parameters: *1/*1 (two wild-type alleles), *1/*x (one of the polymorphic alleles) and *x/*x (two polymorphic alleles). Warfarin and R-warfarin plasma concentrations were higher in the patients with two wild-type alleles (1.57 and 1.08 mg/ml) than in the patients with one (1.29 and 0.76 mg/ml) or two (1.04 and 0.44 mg/ml) polymorphic alleles (Po0.001). S-warfarin plasma concentrations did not differ significantly regarding the CYP2C9 genotype ( Table 2) .
The enantiomeric (S : R) ratio of warfarin concentrations ranging from 0.16 to 2.63, with a mean of 0.59 (0.33), showed marked variability among the patients ( Table 2 ). The S : R concentration ratio was significantly lower among the patients with two wild-type alleles (0.45) than among those with one (0.69) and two polymorphic alleles (1.43) (Po0.001). Furthermore, all the patients with CYP2C9*3/*3 genotype had S : R ratio above 2.00 (range: 2.16-2.65) and five out of six patients with CYP2C9*2/*3 genotype had S : R ratio above 1.00 (range: 0.84-1.47). Two patients with CYP2C9*2/*2 genotype had a higher S : R ratio than those with only one polymorphic allele, but the concentration ratio did not exceed 1.00 (Figure 2 ).
Large interindividual variability was observed in S-warfarin clearance normalized to LBW, ranging from 0.007 to 0.161 ml/min/kg with a mean (SD) of 0.055 (0.027) ml/min/ kg ( Figure 3 ). The patients with two wild-type alleles had a significantly higher mean S-warfarin clearance (0.065 ml/ min/kg) than those with one (0.041 ml/min/kg) or two (0.020 ml/min/kg) polymorphic alleles (Po0.001) ( Table 2) . Although the patients with CYP2C9*1/*2 genotype had a higher mean S-warfarin clearance (0.043 ml/min/kg) than those with CYP2C9*1/*3 genotype (0.038 ml/min/kg), the difference was not significant. The mean S-warfarin clear- ances of the patients with two polymorphic alleles were 0.036 ml/min/kg in CYP2C9*2/*2, 0.020 ml/min/kg in CYP2C9*2/*3 and 0.008 ml/min/kg in CYP2C9*3/*3, but the differences between these three genotypes were not significant.
R-warfarin clearance normalized to LBW ranged from 0.008 to 0.086 ml/min/kg with a mean (SD) of 0.028 (0.012) ml/min/kg. No significant differences were detected between the three CYP2C9 genotype subsets ( Table 2) .
As the patients in our study were mostly elderly people, the majority were taking other drugs besides warfarin, among which some were reported to interfere with warfarin metabolism or plasma protein binding. 19, 20 Therefore, the same analysis for differences between genotype groups was performed on a subgroup of patients with no interfering concomitant drug treatment. Similar effects of CYP2C9 genotype on warfarin metabolism were observed as in the whole study group (Table 2, lower part).
Correlation Analyses
Analysis of the relationship between R-and S-warfarin clearances was performed in order to evaluate the influence of nongenetic factors on warfarin metabolism. The correlation between the two clearances was significant in all three genotype subgroups (Po0.005). The slopes (SE) of the regression lines increased from 0.278 (0.028) for the patients homozygous for wild-type allele to 0.429 (0.048) and 0.640 (0.155) for the patients with one and two polymorphic alleles (P ¼ 0.015), respectively ( Figure 4) . When comparing the regression lines in all the six CYP2C9 genotypes, the slopes can be ordered in the following manner: *1/*1o*1/ *2o*1/*3o*2/*2o*2/*3o*3/*3. However, the test for equality of all the six slopes was not performed due to sparse data.
The relationship between warfarin maintenance dose and S-warfarin clearance was investigated. Correlation analyses showed a significant association between S-warfarin clearance and warfarin dose (Po0.001). In total, 38% of the variance of the warfarin dose was coupled with the variability in the S-warfarin clearance ( Figure 5 ).
Multiple Regression Analysis
Multiple regression analysis was performed on three dependent variables: logarithmically transformed warfarin dose, S-and R-warfarin clearance. As one additional patient was excluded due to missing data on age, 187 patients were included in this analysis. The same predictors were selected as significant by the forward stepwise and block entry method for all three dependent variables.
Genetic characteristics (presence of CYP2C9*1/*x or CYP2C9*x/*x genotype), demographic factors (age, LBW, duration of warfarin therapy, plasma albumin concentration, vegetable and grapefruit intake) and cotreatment with interacting drugs as listed in Table 1 were used as predictors in a multivariate analysis of the logarithmically transformed warfarin dose. Five of the above predictors had a significant influence on warfarin dose requirement ( Table 3 ). The two most important factors were the presence of one and two polymorphic CYP2C9 alleles. Considering polymorphism alone, 27% of the variability in warfarin dose was explained, while other factors explained an additional 10%. Carriers of one or two polymorphic alleles required 39.8 and 63.9% lower warfarin dose respectively, than those with two normal alleles. Warfarin dose requirement further decreased with the patients' age (1.7% per year). On the other hand, warfarin daily dose was higher in the patients who were cotreated with warfarin metabolism inducers (78.1%) and those with higher LBW (0.9%/kg).
To explain the variability of S-and R-warfarin clearance, the same predictors were used with the exception of the (Table 4) . S-warfarin clearance was lower if the patients were carriers of one (1.32 ml/min) or two polymorphic alleles (2.32 ml/min). CYP2C9 genotype alone explained 30% of the variability in the S-warfarin clearance. The concomitant use of potent inhibitors of warfarin metabolism also resulted in a lower S-warfarin clearance (0.45 ml/min). On the other hand, S-warfarin clearance was higher in the patients who were concomitantly taking warfarin metabolism inducers (2.40 ml/min) and those with higher LBW (0.039 ml/min/ kg). All five predictors explained 42% of the variability in Swarfarin clearance.
Six variables were found to have a significant effect on Rwarfarin clearance. The most important factor was concomitant treatment with warfarin metabolism inducers, followed by the patient's age. The patients cotreated with metabolism inducers had a higher R-warfarin clearance (by 0.96 ml/min), while the clearance was lower in older people (0.017 ml/min/year). Cotreatment with potent warfarin metabolism inhibitors also resulted in a lower R-warfarin clearance (by 0.29 ml/min), while in the patients with a higher LBW the clearance was higher (0.011 ml/min/kg). Additionally, R-warfarin clearance was lower in the patients with a higher plasma albumin concentration and those with one polymorphic allele, by 0.0239 ml/min per g/l and 0.17 ml/min, respectively. The 24% of variability in the R-warfarin clearance was explained with this model.
DISCUSSION
The present study was designed to quantify systematically the influence of genetic and demographic factors and concomitant drug treatment on the clearance and CYP2C9 polymorphisms and warfarin metabolism D Herman et al maintenance dose of the anticoagulant drug warfarin in a large and homogeneous group of patients from a welldefined population. We enrolled only patients who were taking warfarin for prevention of thromboembolisms and had no history of underlying conditions that would influence drug requirement and metabolism. So far, several studies have evaluated the influence of CYP2C9 genotype on clinical parameters such as warfarin maintenance dose and susceptibility to bleeding complications, 2,10-16 while fewer have studied the influence on S-warfarin metabolism. [21] [22] [23] Only two studies so far have addressed the influence of CYP2C9 genotype on both the dose requirement and warfarin metabolism. 17, 18 Our results confirm the association of CYP2C9*2 and CYP2C9*3 polymorphic alleles with a marked reduction in warfarin dose requirements. The mean warfarin maintenance dose was highest among patients with CYP2C9*1/*1 genotype and decreased with the number of the polymorphic alleles, with the exception of two patients with CYP2C9*2/*2 genotype. The influence of CYP2C9*3 allele was more pronounced than of CYP2C9*2 allele and was greatest in CYP2C9*3/*3 genotype. The influence of genotype on warfarin dose was further quantified by the multiple regression model, by which it was clearly demonstrated that the presence of one or two polymorphic alleles was the most important factor contributing to the reduction in warfarin dose requirement. In addition, age, concomitant treatment with warfarin metabolism inducers and LBW were found to significantly influence interindividual variability. With all these variables, 37% of the interpatient variability in warfarin dose requirement was explained, which is much higher than the 20% estimated in a previous model by Kamali et al, 18 where only the patient's genotype and age were considered. If genotype and age alone were entered in our model, we could still explain 34% of the dose variability. One possible reason for this discrepancy might be that Kamali's model did not include data on patients with two polymorphic alleles, and that patients with CYP2C9*1/*1 and CYP2C9*1/*2 genotype were combined and compared with those genotyped as CYP2C9*1/*3. This might also be . P-values obtained by block entry of variables are presented. LBW -lean body weight; dummy variables *1/*x and *x/*x denote the presence of one and two polymorphic alleles, respectively; INDUC ¼ dichotomous variable for inducers of warfarin metabolism (its presence was marked by value 1).
CYP2C9 polymorphisms and warfarin metabolism D Herman et al the reason why age was the main factor influencing warfarin maintenance dose in their study, while CYP2C9 genotype was more important than age in ours.
Irrespective of the patients' genotypes, their plasma concentrations of S-warfarin were comparable. This probably reflects the adequate adjustment of warfarin dose in each individual according to the different metabolic activity of the polymorphic CYP2C9 enzyme. Dose adjustment was reflected in lower plasma concentrations of R-warfarin in the patients with polymorphic CYP2C9 alleles. Lower levels of R-warfarin plasma concentrations are therefore not directly related to CYP2C9 polymorphism because CYP2C9 has a minor role in R-warfarin metabolism. 3 Our finding of insignificant difference in R-warfarin clearance among patients with different CYP2C9 genotypes is also in agreement with the minor role of R-warfarin in the overall anticoagulation effect of warfarin.
It was suggested that the S : R plasma concentration ratio is a potentially useful marker for identifying patients with impaired CYP2C9 activity. 17 Such patients would require lower warfarin dose to reach the adequate level of S-warfarin plasma concentration for the sufficient anticoagulant response. However, due to the lower warfarin dose their Rwarfarin plasma concentrations would be lower, leading to the higher S : R ratio. In agreement with this, the patients with two polymorphic alleles had the highest S : R ratio in the present study. Again, the influence of CYP2C9*3 allele was more pronounced than that of CYP2C9*2 allele. The S : R ratio exceeded 1.0 in five out of six patients with CYP2C9*2/ *3 genotype, while all the patients with CYP2C9*3/*3 genotype had an S : R ratio above 2.0.
The influence of various factors on warfarin metabolism was also studied. Our results were in agreement with the findings that CYP2C9*2 and CYP2C9*3 alleles were associated with a reduction in S-warfarin clearance. 17, 18, 22 As R-warfarin clearance does not depend on CYP2C9 polymorphism, the finding of a significant correlation between the S-and R-warfarin clearances in all three genotype subgroups suggests an important involvement of nongenetic factors in warfarin metabolism. As evaluated in our multiple regression model, 30% of interpatient variability in S-warfarin clearance was due to CYP2C9 genotype. An additional 12% of variability can be ascribed to cotreatment with warfarin metabolism inducers or potent inhibitors and LBW. In the previous model, which explained 17% of the variability, the main factor influencing S-warfarin clearance was the patient's age followed by CYP2C9 genotype. 18 Our results did not show any variation of S-warfarin clearance with the patient's age, while R-warfarin clearance and warfarin dose requirement were found to decrease with the patient's age. This is in concordance with studies demonstrating a higher intrinsic sensitivity to the anticoagulant effect of warfarin in elderly patients. 4, 24, 25 As expected, no significant difference in R-warfarin clearance was found when the patients with a different genotype were compared (one-way ANOVA). In our multiple regression model, the two factors that influenced R-warfarin clearance the most were cotreatment with warfarin metabolism inducers and age. Concomitant treatment with potent inhibitors, LBW and plasma albumin concentration were also found to affect R-warfarin clearance. Furthermore, our model suggested that CYP2C9*1/*x genotype weakly affects R-warfarin clearance. This result is difficult to explain; however, it might be due to the low-affinity conversion of R-warfarin to 4 0 -hydroxywarfarin, which is catalyzed by CYP2C9. 3 Another possibility might be the existence of currently unknown environmental determinants or unidentified genetic variants linked to CYP2C9 genotype, which could influence the metabolism of R-warfarin.
A considerable variability was observed within the overall pharmacokinetics and pharmacodynamics of warfarin. A correlation analysis revealed that 38% of the interindividual variability of warfarin maintenance dose resulted from differences in S-warfarin clearance, while the rest could be attributed to interindividual variability in the pharmacodynamic phase. Further studies are needed to clarify the influence of genetic polymorphisms of various proteins involved in blood coagulation on warfarin dose requirement.
In conclusion, the present study confirms a large interindividual variability in warfarin metabolism and dose requirement due to CYP2C9 polymorphism and systematically quantifies the influences of various factors such as age, LBW and concomitant treatment with drugs that interfere with warfarin metabolism. Whether the effect of this polymorphism is sufficient to justify determining the patient's genotype before initiating the therapy remains a matter of argument. Prospective studies in patients in the initiation phase of genotype-based warfarin therapy, with reduced risk of bleeding complications as a primary end point, are necessary to definitely address this issue. The results of the multiple regression analysis presented could serve as a starting point for designing such studies.
METHODS
Patients
In total, 204 outpatients on maintenance warfarin therapy for more than 6 months with a stable INR value between 2.0 and 3.0 (2.5-3.5 for patients with prosthetic heart valves) during the last two visits were enrolled in the study. Of them, 16 were excluded from the study due to missing data or technical reasons. Thus, 188 patients were analyzed. They were receiving warfarin from 6 months to 15 years (mean 3.4 years). Although the main indication for inclusion in the study was atrial fibrillation (n ¼ 157), some patients with deep vein thrombosis (n ¼ 11), prosthetic heart valves (n ¼ 3) and other arterial, coronary or heart diseases (n ¼ 17) were included as well. All the concomitant medications were recorded. A clinical summary was obtained from the records of follow-up visits and a questionnaire. Patients were excluded if they were known to have a history of underlying conditions that influence drug dosage such as cancer, renal or hepatic insufficiency. Since nutrition may influence warfarin dose requirement, the data concerning vegetable and grapefruit intake were obtained from the questionnaires. Vegetable consumption, which is related to vitamin K intake, 1 was evaluated as low or high vegetable intake. Grapefruit intake, which is known to inhibit several CYP, 26 was recorded as yes or no. The patients were followed at the University Medical Centre in Ljubljana, Department for Vascular Diseases (n ¼ 156) and at the General Hospital Murska Sobota (n ¼ 32). All the patients were of Slovenian Caucasian origin. Informed consent was obtained from the patients. The study was approved by the Slovenian Ethics Committee for Research in Medicine (no. 60/02/02).
At 12-16 h after the last warfarin administration, 16 ml of peripheral blood was collected for genotyping and for plasma drug assay.
Genotyping Methods
Genomic DNA was isolated from peripheral leukocytes using a salting-out method. 27 Genotyping of CYP2C9*2 and CYP2C9*3 was performed by polymerase chain reaction followed by restriction enzyme analysis, as validated by Yasar et al. 28 Amplified fragments of exon 3 were digested with AvaII and of exon 7 with NsiI and KpnI.
INR Measurement
Warfarin treatment was monitored by PT in capillary blood, utilizing a combined PT reagent Thrombotestt from AxisShields (Dundee, UK). The clotting times were converted to INR, using tables provided by the manufacturer. The accuracy of the INR measurements was determined by a capillary blood control Coagu Chek PT Controlt from Roche Diagnostics (Basel, Switzerland). The day-to-day variability was 6.7% for an INR value of 2.98 (n ¼ 23). In a single subject reproducibility of INR determination in capillary blood obtained by two finger sticks from different hands was 3.2% for an INR value of 2.5 (n ¼ 50).
Drug Assay
Plasma concentrations of warfarin and its enantiomers, R-and S-warfarin, were determined. 29 Samples were prepared using liquid/liquid extraction. To a 1.0 ml plasma sample, 50 ml of naproxen (100 mg/l) as internal standard and 0.7 ml sulfuric acid (1 mol/l) were added. The samples were vortexed and extracted by 5.0 ml of diethyl ether. Racemic warfarin sodium and naproxen were supplied from Sigma-Aldrich (Steinheim, Germany). Optically pure R-and S-warfarin were obtained from Ultrafine Chemicals (Manchester, UK). HPLC grade acetonitrile and methanol were supplied from Riedel-de Haën (Seelze, Germany); all the other chemicals used were from Merck (Darmstadt, Germany).
The drug assay consisted of two validated HPLC methods, in which two sample aliquots were analyzed separately. The Agilent 1100 Series HPLC system, Agilent Technologies (Palo Alto, USA) equipped with an 1100 model autosampler, thermostat and UV photodiode-array detector was applied to both of the assays. The ODS Hypersil analytical column (5 mm, 100 Â 4.6 mm 2 I.D.), Thermo Hypersil-Keystone (Chesire, UK) coupled with UNIPHASEt C 18 guard column (5 mm, 10 Â 4.6 mm 2 I.D.), Thermo Hypersil-Keystone and with C 18 column prefilter (4 Â 3.0 mm 2 I.D.), Phenomenex (Chesire, UK) were used for achiral separation of warfarin and naproxen. The column temperature was maintained at 251C. The mobile phase consisted of a phosphate buffer (15 mmol/l, pH 3.0), methanol and acetonitrile (52 : 32 : 16). The flow rate was set at 1.2 ml/min. Naproxen and warfarin were detected at 330 and 306 nm, respectively. Using this method, a baseline separation of naproxen, warfarin, 6-, 7-, 8-, 10-and 4 0 -hydroxywarfarin metabolites was achieved. The method was linear in the range from 0.15 to 5.0 mg/l for warfarin. The recovery of the medium concentration (1.0 mg/l) was 61.7% and the intraday precision and repeatability ranged between 99.9-106.6% and 2.3-5.2%, respectively. The interday repeatability was 3.1%.
Warfarin enantiomers were separated on the Chiral-AGP analytical column (5 mm, 100 Â 3.0 mm 2 I.D.), Chromtech (Congleton, UK), connected to the Chiral-AGP guard column (5 mm, 10 Â 3.0 mm 2 I.D.). The column temperature was maintained at 27.51C. The flow rate of the mobile phase consisting of phosphate buffer (50 mmol/l, pH 7.0) and acetonitrile (85 : 15) was set at 0.9 ml/min. Both warfarin enantiomers were detected at 310 nm. Quantification limits for R-and S-warfarin were 0.075 mg/l.
Plasma concentrations of warfarin were calculated from calibration curves derived from warfarin and naproxen response ratio. Additionally, plasma R-and S-warfarin concentrations were calculated from the S-vs R-warfarin response ratio and from the corresponding warfarin concentration.
Determination of Total Protein and Albumin Concentration
Warfarin is categorized as a low liver extraction drug, strongly bound to plasma albumin. Since differences in plasma albumin concentration may influence total warfarin plasma concentration (bound þ free) and consequently determination of warfarin plasma clearance, total protein and albumin concentration in plasma were determined, using the biochemical analyzer Ectachem 250, Eastman Kodak Company (Rochester, New York, USA) according to the manufacturer's instructions.
Pharmacokinetic Analysis
The total plasma warfarin, R-and S-warfarin clearances were determined using a single-point concentration measurement at 12-16 h postdose. Owing to the long elimination half-lives of R-and S-warfarin, around 40 and 25 h, respectively, 22 the warfarin concentration measured in this period approximates the average steady-state concentration (C SS ). 4, 30, 31 Steady-state and drug compliance was assumed in all the patients. Since warfarin bioavailability is almost complete, F was set to unity and clearance could be estimated using the following equation:
where D is the dose administered and t is the dosing interval (24 h). Half of the daily dose of racemic warfarin was taken for calculation of R-and S-warfarin clearances. Individual CYP2C9 polymorphisms and warfarin metabolism D Herman et al clearances were divided by the patients' LBW for statistical comparisons. LBW was calculated on the basis of actual weight and height using the James equations. 32 
Statistical Analysis
Statistical analysis was performed using SPSS 11.0 statistic software (SPSS Inc. Chicago, IL, USA). The one-way ANOVA followed by the LSD test for post hoc comparisons was applied to evaluate the influence of CYP2C9 genotype on warfarin pharmacokinetics. As the daily maintenance dose, warfarin, R-and S-warfarin concentrations and S : R warfarin concentration ratio failed the Kolmogorov-Smirnov test for normality, ANOVA and post hoc tests were performed on logarithmically transformed variables. The significance level was set at Po0.05.
The relationship between R-and S-warfarin clearances was examined for various CYP2C9 genotypes and the equality of the slopes of several regression lines was tested. 33 Multiple regression models were built to estimate the influences of genetic and demographic factors on the logarithmically transformed warfarin dose and R-and Swarfarin clearances. The categorical variables CYP2C9 genotype (*1/*1, *1/*x or *x/*x) and inhibition of warfarin metabolism (none, weak, potent) were recoded into dummy variables by the simple contrast method. The block entry of variables in a single step and forward stepwise (P entry p0.05, P removal X0.10) methods were used for selecting the predictor variables.
